.png)
Agenzia Italiana del Farmaco
Direct communication with healthcare professionals on ADAKVEO (crizanlizumab) - Direct communication with healthcare professionals on ADAKVEO (crizanlizumab)
Direct communication with healthcare professionals on ADAKVEO (crizanlizumab)
ADAKVEO (crizanlizumab): Phase III study (CSEG101A2301) shows no superiority of crizanlizumab over placebo.
Summary:
- Preliminary results from the phase III study CSEG101A2301 (STAND) did not show a difference between crizanlizumab and placebo in annualized rates of vaso-occlusive crises leading to a healthcare visit over the first-year post randomization.
- The preliminary results do not suggest new safety concerns with crizanlizumab. However, higher rates for grade ≥3 treatment-related adverse events were reported for crizanlizumab compared to placebo.
- Further evaluation of the data from study CSEG101A2301 and their potential impact on the benefit-risk balance of crizanlizumab is currently ongoing by EMA. The final conclusions and recommendations will be communicated as soon as the evaluation has been completed.
- While this evaluation is ongoing, physicians should consider the individual benefit and risks when making therapeutic decisions regarding the use of crizanlizumab.
Published on: 14 February 2023
AIFA e Procura di Velletri firmano il protocollo d’intesa per il contrasto alla violenza di genere
...
Vai al post →
💊 Se non sei un medico, non fare il medico. L’uso improprio degli #antibiotici ne limita l’efficaci...
Vai al post →
💊 Se non sei un medico, non fare il medico. L’uso improprio degli #antibiotici ne limita l’efficaci...
Vai al post →
📅 #1dicembre - Giornata mondiale della lotta contro l’AIDS
🔴 #AIFA si illumina di rosso, colore s...
Vai al post →
🔬 Secondo Bando #AIFA di ricerca indipendente 2025
📑 107 progetti presentati, per un finanziament...
Vai al post →
👥💬 Parte “AIFA Ascolta”, uno spazio di dialogo con associazioni, reti e federazioni dei #pazienti,...
Vai al post →
